Brief: Biophytis Extends Treatment Period For Sarconeos Study

Biophytis SA

28/08/2020 18:24

Aug 28 (Reuters) - BIOPHYTIS SA  ALBPS.PA :
    * PROVIDES AN UPDATE ON SARA-INTEREST, A PHASE 2B CLINICAL
TRIAL
EVALUATING THE EFFICACY OF SARCONEOS (BIO101) IN THE TREATMENT
OF SARCOPENIA
    * RE OPENING OF INVESTIGATION SITES IN BELGIUM AND IN THE US
    * TREATMENT PERIOD EXTENDED BY 3 MONTHS BASED ON A REVIEW OF
THE
DSMB AND THE FAVORABLE RISK PROFILE OF SARCONEOS (BIO101)
    * AS A RESULT OF DELAYS DUE TO COVID-19, AND PROVIDED TOP
LINE
RESULTS TO COME, NO INTERIM ANALYSIS WILL BE UNDERTAKEN BY THE
DSMB
    * AS A RESULT OF PROTOCOL CHANGES, AND DEPENDING ON
PANDEMIC, LAST
PATIENT OUT FROM THE SARA-INTEREST STUDY IS NOW EXPECTED AT END
OF 2020

Source text: https://bit.ly/3gEFpwD
Further company coverage:  ALBPS.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))